PEDIATRIC RESEARCH, vol.72, no.5, pp.507-512, 2012 (SCI-Expanded)
BACKGROUND: Proadrenomedullin (pro-ADM) for the diagnosis of proven and clinical sepsis in a newborn cohort including preterm newborns has not been investigated. We aimed to investigate the value of pro-ADM as a new marker by comparing it with conventional markers in neonatal sepsis (NS).